Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-GPC3 T Cells in Advanced Hepatocellular Carcinoma
NCT03980288Phase 1Completed
- Sponsor
- Zhejiang University
- Start
- Jul 2019
- Primary completion
- Dec 2020
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CT011 in hepatocellular carcinoma (HCC), sponsored by Zhejiang University. Primary endpoints: Dose Limiting Toxicity at 28 days and Maximum Tolerated Dose at 28 days. Started Jul 2019; status: completed.
02
Drugs
CT011
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03980288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03980288.